
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-05-06-2015
- Volume 11
- Issue 5
SGS Completes Expansion at Mumbai Facility
Stability testing and UPLC capabilities highlight expansion at Mumbai, India facility of SGS Life Science Services.
SGS Life Science Services, a clinical and bioanalytical contract solutions provider, has announced the completion of an expansion at its Mumbai, India, facility with validation of new equipment currently underway; an official opening of the laboratory is planned for May 20, 2015.
The expansion has seen the previous 1,393-square meter laboratory space more than double in size, to 3,400 square meters; once validation is completed, the laboratory will act as a dedicated cGMP pharmaceutical testing site. The workforce has increased from 65 to 115, with the potential for up to another 40 employees in the additional facilities, according to a company statement.
Investment at the laboratory focused on increasing stability chamber capacity, and in supporting chromatography equipment, including new UPLC capabilities. The Mumbai facility now has the largest stability testing facility in the SGS Life Science Services’ global network, with the expansion driven by the increased demand from both local and international customers, the company reports.
Three new 100-cubic meter capacity stability chambers have been installed for 21 CFR part 11-compliant short term, long term, and accelerated studies, and covers all the International Conference of Harmonisation (ICH) conditions, as well as flexibility for specific client conditions. The Mumbai expansion follows SGS’s renovation of its Chennai, India, laboratory in 2014, increasing laboratory space within the facility. The number of employees increased from 60 to 75, with the flexibility to further accommodate up to 90.
Source: S
Articles in this issue
about 11 years ago
Better Control of the API Supply Chain?about 11 years ago
Big Pharma Feeds Big CMO Growthabout 11 years ago
Capsugel Produces DPI Phase 2 Trial Suppliesabout 11 years ago
Chinese API Manufacturer Warned for Data Integrity Issuesabout 11 years ago
Mylan Recalls Injectables Due to Visible Particulate Matterabout 11 years ago
FDA Releases Final Biosimilar Guidanceabout 11 years ago
Vetter Serializes First Product for South Koreaabout 11 years ago
IDT Biologika Vaccine Facility Recognizedabout 11 years ago
Serialization: Deja Vu All Over Again?about 11 years ago
Gauging Change in Europe’s Sterile Manufacturing Market



